Ignite Creation Date:
2024-05-06 @ 6:53 PM
Last Modification Date:
2024-10-26 @ 2:57 PM
Study NCT ID:
NCT05828836
Status:
COMPLETED
Last Update Posted:
2023-10-31
First Post:
2023-04-12
Brief Title:
Allopurinol and Quality of Life in Liver Cirrhosis
Sponsor:
Tanta University
Organization:
Tanta University
Study Overview
Official Title:
the Impact of Allopurinol of HRQOL in Cirrhotic Patients
Status:
COMPLETED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study aims to evaluate the impact of allopurinol on patients related quality of life
Detailed Description:
Cirrhosis is the late stage of liver damage and possess two phases The shift from compensated to decompensated cirrhosis is characterized by the onset of complications which are associated with substantial morbidity and negative Impact on quality of life QOLCirrhosis and its complications have a substantial economic social and personal impact on affected patients as well as their families and caregivers
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None